Key Points
- David Moatazedi sold 116,720 shares of Evolus on March 17 at an average price of $4.89 for about $570,761, cutting his ownership by 15.88% to 618,369 shares valued at roughly $3.02M.
- Evolus shares opened at $4.83 (one‑year range $4.09–$13.66) and the company missed quarterly EPS expectations with $0.00 versus a $0.09 consensus while reporting $90.3M in revenue; market cap is about $314M and the PE is negative.
- The stock carries a "Moderate Buy" consensus with a $16 average target amid mixed analyst ratings (4 Buy, 1 Hold, 1 Sell), and institutional investors hold roughly 90.7% of the company.
Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 29,996 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $146,680.44. Following the transaction, the insider owned 430,542 shares in the company, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Rui Avelar also recently made the following trade(s):
- On Monday, December 22nd, Rui Avelar sold 2,261 shares of Evolus stock. The stock was sold at an average price of $7.15, for a total transaction of $16,166.15.
Evolus Price Performance
Shares of NASDAQ:EOLS traded down $0.08 during trading hours on Thursday, hitting $4.76. The company's stock had a trading volume of 26,137 shares, compared to its average volume of 1,354,300. The firm's fifty day moving average price is $4.83 and its 200 day moving average price is $6.08. The company has a market capitalization of $309.36 million, a price-to-earnings ratio of -5.86 and a beta of 1.02. Evolus, Inc. has a 52 week low of $4.09 and a 52 week high of $13.66.
Evolus (NASDAQ:EOLS - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analysts' expectations of $89.58 million. On average, equities research analysts predict that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
EOLS has been the subject of a number of research reports. Weiss Ratings restated a "sell (e+)" rating on shares of Evolus in a research report on Monday, December 22nd. Needham & Company LLC reissued a "hold" rating on shares of Evolus in a research note on Wednesday, December 24th. BTIG Research reissued a "buy" rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. HC Wainwright dropped their price target on Evolus from $20.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Finally, Mizuho set a $15.00 target price on shares of Evolus in a research note on Wednesday, February 4th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $16.00.
Read Our Latest Report on Evolus
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company's stock valued at $400,000 after buying an additional 1,838 shares during the period. Millennium Management LLC lifted its position in shares of Evolus by 1.7% during the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock worth $16,746,000 after purchasing an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in shares of Evolus during the first quarter worth $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Evolus by 36.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock valued at $1,883,000 after buying an additional 41,513 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock valued at $841,000 after buying an additional 57,987 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
